Johnson & Johnson Skin Drug Gets Positive Opinion From EU Drug Regulator
By Adria Calatayud
Johnson & Johnson's Icotyde drug got a favorable opinion from a key committee at the European Medicines Agency as a treatment for chronic skin condition psoriasis, paving the way for its approval in the European Union.
The EMA said Friday that its human medicines committee recommended granting marketing authorization for Icotyde. The drug already received approval from the U.S. Food and Drug Administration in March.
The European Commission, the EU's executive arm, is now due to decide on the drug's approval.
Icotyde works by blocking the action of a protein called interleukin-23, which plays a key role in the inflammation seen in the disease. The agency said Icotyde would be the first oral medicine of its kind to be approved in the EU, where injectable medicines that target the same protein are already available.
J&J executives said during an earnings call last week that the drug had significant momentum since its launch in the U.S.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 24, 2026 07:17 ET (11:17 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
3 Stocks to Invest In With More Room to Run
United States